^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)

i
Other names: E/C/F/TAF
Associations
Trials
Company:
Gilead
Drug class:
Cytochrome P450 inhibitor, Integrase inhibitor, Nucleoside analog reverse transcriptase inhibitor
Associations
Trials
30d
Trial completion date
|
Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)
2ms
Enrollment open
|
Tybost (cobicistat) • Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) • ritonavir
5ms
Bictegravir in the Elderly Living With HIV (BICEP) (clinicaltrials.gov)
P=N/A, N=162, Active, not recruiting, State University of New York at Buffalo | Trial completion date: Jul 2023 --> Dec 2024 | Trial primary completion date: Jul 2023 --> Dec 2024
Trial completion date • Trial primary completion date
|
Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)
8ms
New P4 trial
|
Tybost (cobicistat) • Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) • ritonavir
12ms
B-free Multistage Trial (clinicaltrials.gov)
P4, N=210, Enrolling by invitation, Insel Gruppe AG, University Hospital Bern | Recruiting --> Enrolling by invitation | Trial completion date: Aug 2027 --> Dec 2027 | Trial primary completion date: Aug 2025 --> Nov 2025
Enrollment status • Trial completion date • Trial primary completion date
|
CD4 (CD4 Molecule)
|
Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)